Cell therapies in ovarian cancer.

Details

Serval ID
serval:BIB_10D5AD530F84
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Cell therapies in ovarian cancer.
Journal
Therapeutic advances in medical oncology
Author(s)
Sarivalasis A., Morotti M., Mulvey A., Imbimbo M., Coukos G.
ISSN
1758-8340 (Print)
ISSN-L
1758-8340
Publication state
Published
Issued date
2021
Peer-reviewed
Oui
Volume
13
Pages
17588359211008399
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Epithelial ovarian cancer (EOC) is the most important cause of gynecological cancer-related mortality. Despite improvements in medical therapies, particularly with the incorporation of drugs targeting homologous recombination deficiency, EOC survival rates remain low. Adoptive cell therapy (ACT) is a personalized form of immunotherapy in which autologous lymphocytes are expanded, manipulated ex vivo, and re-infused into patients to mediate cancer rejection. This highly promising novel approach with curative potential encompasses multiple strategies, including the adoptive transfer of tumor-infiltrating lymphocytes, natural killer cells, or engineered immune components such as chimeric antigen receptor (CAR) constructs and engineered T-cell receptors. Technical advances in genomics and immuno-engineering have made possible neoantigen-based ACT strategies, as well as CAR-T cells with increased cell persistence and intratumoral trafficking, which have the potential to broaden the opportunity for patients with EOC. Furthermore, dendritic cell-based immunotherapies have been tested in patients with EOC with modest but encouraging results, while the combination of DC-based vaccination as a priming modality for other cancer therapies has shown encouraging results. In this manuscript, we provide a clinically oriented historical overview of various forms of cell therapies for the treatment of EOC, with an emphasis on T-cell therapy.
Keywords
adoptive cell therapy (ACT), cancer immunotherapy, neoantigens, ovarian cancer, tumor-infiltrating lymphocyte (TIL)
Pubmed
Web of science
Open Access
Yes
Create date
25/05/2021 14:29
Last modification date
04/09/2021 6:34
Usage data